NCT03559192已完成2 期
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects With Major Depressive Disorder
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 181
- 试验地点
- 49
- 主要终点
- Change From Treatment Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Treatment Week 6 in Participants Who Were Non-Responders During Placebo Lead-in Period
研究概览
简要总结
The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in participants with Major Depressive Disorder (MDD) partially responsive to selective serotonin reuptake inhibitor/ serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) treatment in terms of reduction of symptoms of depression, as assessed by the change from baseline on the Montgomery Asberg Depression Rating Scale (MADRS) in non-responders during the placebo lead-in period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a Body Mass Index (BMI) between 18 and 35 kilogram per meter square (kg/m^2) inclusive (BMI = weight/height^2)
- •Participants must be medically stable based on clinical laboratory tests, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening and baseline
- •Participants must have a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of Major Depressive Disorder (MDD)
- •The current episode should be less than 18 months
- •Participants should be currently treated with an SSRI or SNRI at an adequate dose and for at least 6 weeks but no more than 12 months
- •Have a Montgomery-Asberg Depression Rating Scale (MADRS) total score greater than or equal to (>=) 25 at screening
- •A woman of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test before the first dose
排除标准
- •History of documented gastric disease (including documented peptic ulcer disease, gastritis, upper gastrointestinal [GI] bleeding, esophagitis, or any GI precancerous condition), current clinically evident GI complaints
- •Chronic use of a proton pump inhibitors (PPIs). History of incidental use of PPIs is allowed but should have been stopped at least 4 weeks before screening. A history of chronic nonsteroidal anti-inflammatory drug (NSAID) or aspirin use. (Low dose aspirin for example in cardiovascular disease prevention is allowed)
- •Has a history of alcohol use disorder within the past year
- •Has failed (no more than 25 percent [%] response on Antidepressant Treatment History Questionnaire [ATRQ]) three or more antidepressant treatments including the current Selective serotonin reuptake inhibitor/ serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) during the current depressive episode despite an adequate dose (per ATRQ) and duration (at least 6 weeks)
- •Has signs or symptoms of Cushing's Disease, Addison's Disease, primary amenorrhea, or other evidence of significant medical disorders of the hypothalamus pituitary adrenal (HPA) axis
- •Participant has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 3 months before the planned first dose of study drug or has participated in any interventional clinical studies on MDD in the previous 1 year or is currently enrolled in an interventional study
- •Has one or more of the following diagnoses:
- •A primary DSM (5th edition) diagnosis of generalized anxiety disorder (GAD), panic disorder, obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD). Participants with comorbid GAD, social anxiety disorder (SAD), or panic disorder for whom MDD is considered the primary diagnosis are not excluded
- •A current diagnosis or diagnosis in the past 1 year of psychotic disorder, MDD with psychosis, anorexia nervosa or bulimia nervosa, chronic fatigue syndrome, bipolar disorder (BD), mental retardation, antisocial or borderline personality disorder, autism spectrum disorder
- •Has a current or recent history of clinically significant suicidal ideation within the past 6 months, corresponding to a score of 4 (active suicidal ideation with some intent to act, without specific plan) or 5 (active suicidal ideation with specific plan and intent) for ideation on the Colombia suicide severity rating scale (C-SSRS), or a history of suicidal behavior within the past 1 year
- •Ongoing psychological treatments (example, Cognitive Behavior Therapy, Interpersonal Psychotherapy, Psychodynamic Psychotherapy, etcetera [etc.]), initiated within 1 month prior to the screening phase. A participant who has been receiving ongoing psychological treatment for a period of greater than 1 month from the screening visit is eligible, if the investigator deems the psychological treatment to be of stable duration and frequency
- •Participant has a history of substance use disorder according to DSM-5 criteria, except nicotine or caffeine, within 6 months before screening. Mild cases can be reviewed on a case by case basis. Participants who have completed a treatment for (alcohol) addiction more than 1 year prior to first dose administration, may be included if the risk of relapse is considered minimal, total duration of alcohol use disorder was less than a year, and no significant abnormalities are shown in clinical laboratory or other pre-dose safety assessments
- •Participant has used:
- •Monoamine oxidase inhibitors (MAOIs) within 12 weeks before screening
- •St. John's wort, ephedra, ginkgo, ginseng, or kava within 2 weeks before screening
- •Antipsychotic drugs (D2-antagonists) within 2 weeks before screening. However, Seroquel (quetiapine) in a dose less than or equals to (<=)100 milligram (mg) is allowed when used in a stable dose for at least 8 weeks prior to screening. Quetiapine treatment should be continued unchanged during the study
- •Opioids within 2 weeks before screening
- •Psychostimulants such as methylphenidate or dextroamphetamine within 2 weeks before screening
- •Psychotropics with antidepressant effects such as atomoxetine or thyroid supplementation, in addition to their SSRI or SNRI treatment within 2 weeks before screening
- •Participant is unable to stop the following medication from the baseline visit (Visit 2) and throughout the study (tapering during screening period allowed): Any hypnotics including but not limited to: i. Benzodiazepines when used only as needed (PRN) are not allowed ii. Sedating antihistamines, including chronic use of diphenhydramine iii. Continuous use of zolpidem, zoplicon, eszopiclone and ramelteon. Note: Nonbenzodiazepines sleep aids (including: zolpidem, zaleplon, and eszopliclone) are allowed on an as needed (PRN) basis during the study but NOT within 24 hours before being in the clinic and not more than 2 nights in a row iv. S-adenosyl methionine (SAMe) v. Melatonin, agomelatine
- •Has received any prior treatment with electroconvulsive therapy, vagal nerve stimulation, or a deep brain stimulation device or treatment with ketamine or esketamine for MDD
研究组 & 干预措施
Lead-in Period: Placebo
Placebo Comparator
Participants will receive matching placebo for the entire duration of the lead-in period.
干预措施: Placebo (Drug)
Treatment Period: JNJ-67953964 or Placebo
Experimental
Participants who respond or do not respond (based on reduction from lead-in baseline in MADRS) in the placebo lead-in period will receive either matching placebo or 10 (2*5) milligram (mg) JNJ-67953964 capsules in a 1:1 ratio for 6 weeks.
干预措施: JNJ-67953964 (Drug)
Treatment Period: JNJ-67953964 or Placebo
Experimental
Participants who respond or do not respond (based on reduction from lead-in baseline in MADRS) in the placebo lead-in period will receive either matching placebo or 10 (2*5) milligram (mg) JNJ-67953964 capsules in a 1:1 ratio for 6 weeks.
干预措施: Placebo (Drug)
Withdrawal Period: Placebo
Placebo Comparator
Participants who complete the double-blind treatment period prior to the end of Week 11 will receive matching placebo for the remaining time of the treatment phase of the study.
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Treatment Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Treatment Week 6 in Participants Who Were Non-Responders During Placebo Lead-in Period
时间窗: Treatment Baseline up to Week 6 of DB-treatment period
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change from baseline indicates improvement.
次要结局
- Change From Treatment Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Treatment Week 6 (eITT Population)(Treatment Baseline up to Week 6 of DB-treatment period)
- Change From Treatment Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score at Treatment Week 6 (eITT Population)(Treatment Baseline up to Week 6 of DB-treatment period)
- Change From Treatment Baseline in MADRS Total Score at Treatment Week 6(Treatment Baseline up to Week 6 of DB-treatment period)
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) During DB Treatment Period(Up to Week 6)
- Change From Treatment Baseline in SHAPS Total Score at Treatment Week 6 (fITT)(Treatment Baseline up to Week 6 of DB-treatment period)
- Number of Participants With Self-Assessment of Treatment Experience (SATE) Questionnaire at Treatment Week 6 (eITT Population)(Treatment Week 6)
- Number of Participants With SATE Questionnaire at Treatment Week 6 (fITT Population)(Treatment Week 6)
- Change From Treatment Baseline in CGI-S Score at Treatment Week 6 (fITT Population)(Treatment Baseline up to Week 6 of DB-treatment period)
- Change From Treatment Baseline in HAM-A6 Total Score at Treatment Week 6 (fITT)(Treatment Baseline up to Week 6 of DB-treatment period)
- Change From Treatment Baseline in SIGH-A Score at Treatment Week 6 (fITT Population)(Treatment Baseline up to Week 6 of DB-treatment period)
- Change From Treatment Baseline in Clinical Global Impression - Severity (CGI-S) Score at Treatment Week 6 (eITT Population)(Treatment Baseline up to Week 6 of DB-treatment period)
- Change From Treatment Baseline in SMDDS Total Score at Treatment Week 6 (fITT Population)(Treatment Baseline up to Week 6 of DB-treatment period)
- Change From Treatment Baseline in Hamilton Anxiety Scale 6 (HAM-A6) Total Score at Treatment Week 6 (eITT Population)(Treatment Baseline up to Week 6 of DB-treatment period)
- Maximum Observed Plasma Concentration (Cmax) of JNJ-67953964(Week 1: Day 29, Week 3: Day 43, Week 6 (Day 64))
- Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC[0-24h]) of JNJ-67953964(0 to 24 hours Post dose on Week 1: Day 29, Week 3: Day 43, Week 6: Day 64)
- Area Under Plasma Concentration-Time Curve at Steady State (AUCss) of JNJ-67953964(Week 1: Day 29, Week 3: Day 43, Week 6: Day 64)
- Predose (Trough) Plasma Concentration (C0h) of JNJ-67953964(Predose on Week 1: Day 29, Week 3: Day 43, Week 6: Day 64)
- Change From Treatment Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) Score at Treatment Week 6 (eITT Population)(Treatment Baseline up to Week 6 of DB-treatment period)
研究者
研究点 (49)
Loading locations...
相似试验
已完成
2 期
A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum DisorderAutism Spectrum DisorderNCT03664232Janssen Research & Development, LLC78
已完成
2 期
A Study of JNJ-55308942 in the Treatment of Bipolar DepressionBipolar DisorderNCT05328297Janssen Pharmaceutica N.V., Belgium116
已完成
2 期
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes MellitusObesity and Diabetes Mellitus, Type 2NCT03586830Janssen Research & Development, LLC196
终止
2 期
A Study of JNJ-63733657 in Participants With Early Alzheimer's DiseaseAlzheimer DiseaseCognitive DysfunctionDementiaNCT04619420Janssen Research & Development, LLC523
已完成
2 期
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related PainPain, BurningPain, CrushingPain, MigratoryPain, RadiatingPain, SplittingNCT00929188Janssen Research & Development, LLC100